sunitinib g.l. pharma
g.l. pharma gmbh - sunitinibas - kietosios kapsulės - 25 mg - sunitinib
sunitinib g.l. pharma
g.l. pharma gmbh - sunitinibas - kietosios kapsulės - 50 mg - sunitinib
sunitinib zentiva
zentiva k.s. - sunitinibas - kietosios kapsulės - 12,5 mg - sunitinib
sunitinib zentiva
zentiva k.s. - sunitinibas - kietosios kapsulės - 50 mg - sunitinib
sunitinib accord
accord healthcare s.l.u. - sunitinibas - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antinavikiniai vaistai - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
abiraterone sandoz
sandoz d.d. - abiraterono acetatas - plėvele dengtos tabletės - 500 mg - abiraterone
sorafenib sandoz
sandoz d.d. - sorafenibas - plėvele dengtos tabletės - 400 mg - sorafenib
tatica
egis pharmaceuticals plc - abiraterono acetatas - plėvele dengtos tabletės - 250 mg - abiraterone
tatica
egis pharmaceuticals plc - abiraterono acetatas - plėvele dengtos tabletės - 500 mg - abiraterone
abiraterone mylan
mylan ireland limited - abiraterono acetatas - prostatos navikai - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.